<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>肿瘤资讯 | wechat-feeds</title><link>http://MjM5Nzc4MDk2MA.favicon.privacyhide.com/favicon.ico</link><description>分享肿瘤领域最新进展，传播正确肿瘤防治理念，提高全社会对肿瘤的关注！新浪微博：@肿瘤资讯</description><managingEditor> (hellodword)</managingEditor><pubDate>Fri, 19 Feb 2021 20:41:18 +0800</pubDate><image><url>http://MjM5Nzc4MDk2MA.favicon.privacyhide.com/favicon.ico</url><title>肿瘤资讯 | wechat-feeds</title><link>http://MjM5Nzc4MDk2MA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>【2742】牛晓辉教授：坚持多学科诊疗，做好排兵布阵，将药物治疗与外科治疗发挥极致</title><link>https://mp.weixin.qq.com/s/pDUbOSEdAdLp9wdQnwyWiw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/0Q6qiaRIrCLjyswRx0wXsKAHg5LKsOp3lGm5F77gPTPIdy6TiaVpLVPibUkoVNsJRg2ZkfofGGGUOEffxicuOEicqvg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>近年来，多学科诊疗模式广泛应用，正逐步成为肿瘤治疗的主流模式。]]></content:encoded><pubDate>Fri, 19 Feb 2021 18:51:44 +0800</pubDate></item><item><title>【2021 ASCO-GI】林榕波教授点评：术前mFOLFIRINOX联合或不联合放疗用于胰腺交界性可切除腺癌的疗效</title><link>https://mp.weixin.qq.com/s/r8i4mueapc10kzv60dG1kA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/0Q6qiaRIrCLjyswRx0wXsKAHg5LKsOp3llCpicvDXnuNtDHFOyXHNKUIIC3y8j0lJLfZ8MN5icicAM07UYNFLeosFA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>术前mFOLFIRINOX联合或不联合放疗用于胰腺交界性可切除腺癌的疗效。]]></content:encoded><pubDate>Fri, 19 Feb 2021 18:51:44 +0800</pubDate></item><item><title>“GIST 新时空”专栏 | 赵传华教授解析：全面的NGS检测在GIST分子诊断中的应用</title><link>https://mp.weixin.qq.com/s/ofPnLTmxICG11lanA9QR0A</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/0Q6qiaRIrCLjyswRx0wXsKAHg5LKsOp3lxORUurPRcHbfp2C2TlW0pOIibs9HBI3mIQhbJzzico5JhFNYGm5wtnBA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>赵传华教授解析：全面的NGS检测在GIST分子诊断中的应用]]></content:encoded><pubDate>Fri, 19 Feb 2021 18:51:44 +0800</pubDate></item><item><title>【用“实例”说话】巨块型肝癌伴微血管癌栓，多学科诊疗使患者获得长生存</title><link>https://mp.weixin.qq.com/s/DlCBx9pHhvd6-C4j4xWzng</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/0Q6qiaRIrCLjyswRx0wXsKAHg5LKsOp3lssukHXFKtYPyRwSmgrAWUYetOuMTZKBjVNUCQjDibz83l7Wpz9KPbQw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>病例分享：一例临床分期虽为Ⅰb期，但术后病理提示多灶脉管癌栓的患者，经过术后多学科早期干预，全身与局部相结合，获得长生存的故事。]]></content:encoded><pubDate>Fri, 19 Feb 2021 18:51:44 +0800</pubDate></item><item><title>世界癌症负担数据| 这四种因素与癌症关系太紧密了！</title><link>https://mp.weixin.qq.com/s/ki1UvgF3y2c1cAvENk1RyA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/EahiazIswHwXxjic4PcKTdsoplibMFleIBziaRvuC4dySYwztfdMDtib5iaH15icCIwbbRWNyBOQ6RP1RnUznM1lCsQCg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>分享一篇文章。]]></content:encoded><pubDate>Fri, 19 Feb 2021 18:51:44 +0800</pubDate></item><item><title>【2741】陈晓红教授：坚守初心，做好角色担当，打造核心竞争力</title><link>https://mp.weixin.qq.com/s/p8DuMWph31v6R_twcYWVlg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/0Q6qiaRIrCLhtlXSPEzgIicjtXYVJRC0NQiceOXmFc7SYeiapWgYtnrM9nwT4W7faicZhPaicsgfytwIYT5PSFibtO1wg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>科技进步与技术创新带来了医疗模式的巨大变化，多学科诊疗模式（MDT）已经成为肿瘤治疗的主流模式。]]></content:encoded><pubDate>Thu, 18 Feb 2021 18:57:05 +0800</pubDate></item><item><title>陈功教授|国内首个微卫星不稳定检测试剂盒获批，开创MSI检测“有证”时代！</title><link>https://mp.weixin.qq.com/s/adhghZemj2Tn5Wv8PgfABQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/0Q6qiaRIrCLhtlXSPEzgIicjtXYVJRC0NQ7LNdbTmFsoN7ag4j1ibjO94C7jv26pk3mGJ0hGkQxpCv5QuhlRhEicAw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>国内首个微卫星不稳定检测试剂盒获批，开创MSI检测“有证”时代！]]></content:encoded><pubDate>Thu, 18 Feb 2021 18:57:05 +0800</pubDate></item><item><title>【2021 ASCO-GI】林榕波教授：Infigratinib治疗FGFR2基因融合/重排的晚期胆管癌，疗效可期</title><link>https://mp.weixin.qq.com/s/U_zd-FxiPSgxLgDMkzBAtQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/0Q6qiaRIrCLhtlXSPEzgIicjtXYVJRC0NQIT8djLJxE10RqfkD8cjAAxL8uQNGMe6La8ib2J2cHibibsvKww0LqBa2Q/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>福建省肿瘤医院【十邑论坛】与良医汇【肿瘤资讯】共同推出重磅研究解读系列文章，由福建省肿瘤医院的林榕波教授就ASCO-GI会议中公布的重要研究进行深度点评与解析。]]></content:encoded><pubDate>Thu, 18 Feb 2021 18:57:05 +0800</pubDate></item><item><title>在我们身边的致癌物，内附IARC公布的121种I类致癌物名单</title><link>https://mp.weixin.qq.com/s/gSdc8S5O9FCIGQq_pbKLgg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/EahiazIswHwVS9s7Ziayg6fqaU7a8LO7oxRA8Tbib5uTyVPaEaBkoQLp2VicUFC05DFLqwUkrBcJKkEve8narlWaBA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>分享一篇文章。]]></content:encoded><pubDate>Thu, 18 Feb 2021 18:57:05 +0800</pubDate></item><item><title>【2740】周志伟教授：多学科携手新技术，助力肿瘤患者获益最大化</title><link>https://mp.weixin.qq.com/s/XiAvT1gexTbwvTXXDk29JA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/0Q6qiaRIrCLjEYCiabiarw28DxFcbtYnPGvoXyzdsEPKy0TcF8O2Mx28EhMHKtac1rf9iakak2NRpJmOic0FkA8hMVw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>]]></content:encoded><pubDate>Wed, 17 Feb 2021 19:14:18 +0800</pubDate></item><item><title>【2021 ASCO-GI】林榕波教授点评ClarIDHy研究：Ivosidenib为IDH1突变型晚期胆管癌治疗添生机</title><link>https://mp.weixin.qq.com/s/ylZy_2EybvbEuhglwpRVRA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/0Q6qiaRIrCLjEYCiabiarw28DxFcbtYnPGv6uSX3AXWlkQvY2WjKrJnbNSDFWxDpowSpTQMDrbITkoaicQX3mAnjQg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>]]></content:encoded><pubDate>Wed, 17 Feb 2021 19:14:18 +0800</pubDate></item><item><title>赵明芳教授：达伯舒®获批一线非鳞非小细胞肺癌适应证，更高可及性惠及更多患者</title><link>https://mp.weixin.qq.com/s/r-mQzhvfBwLF5UOXTHn6EA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/0Q6qiaRIrCLjEYCiabiarw28DxFcbtYnPGvw3lgOo3anGxlCFhLKzfAeBpKH1z0R7fVhowPUfHvbxdTRuQL3bjllw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>]]></content:encoded><pubDate>Wed, 17 Feb 2021 19:14:18 +0800</pubDate></item><item><title>【2月19—21日】2021 ASCO-GU进展与解读蓄势待发！</title><link>https://mp.weixin.qq.com/s/FaXI64tzW0SfPnyIYJUHUg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/0Q6qiaRIrCLjEYCiabiarw28DxFcbtYnPGvtc0C0ib8WKCHfKnrNJESgQuVdExRcyt1Pfr1KvV8JlsGibrl5mL0PpfA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>]]></content:encoded><pubDate>Wed, 17 Feb 2021 19:14:18 +0800</pubDate></item><item><title>【2739】叶定伟教授：MDT模式下，肿瘤外科向规范化、精准化迈进</title><link>https://mp.weixin.qq.com/s/1amwW4GAaoZwpLWkcX1Img</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/0Q6qiaRIrCLiamNZlLFF6C0iaicNurmYm3aNkDH7diahSDBYiadSo1ESpK4ou1foKODJwtBiaruiceRpC2Kf5CjHLujicfw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>整理：肿瘤外科资讯来源：肿瘤外科资讯随着肿瘤诊疗理念的不断升级，多学科诊疗模式（MDT）已经成为肿瘤治疗的主]]></content:encoded><pubDate>Tue, 16 Feb 2021 19:30:02 +0800</pubDate></item><item><title>【中国好声音】林少俊教授团队在肿瘤放疗学国际权威期刊Radiotherapy and Oncology发表鼻咽癌靶区改良研究成果</title><link>https://mp.weixin.qq.com/s/OekZwA3nE5ERcJQRWPmN1Q</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/0Q6qiaRIrCLiamNZlLFF6C0iaicNurmYm3aNaEgYbSfj9SfVVfhITgDc1MCNWV6U8IE1d9FXSu35IZnK8GBftb9dqw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>近日，福建省肿瘤医院头颈放疗科郭巧娟博士/郑亚涵硕士为第一作者，林少俊教授为通讯作者在肿瘤放疗界权威杂志Radiotherapy and Oncology上发表论文]]></content:encoded><pubDate>Tue, 16 Feb 2021 19:30:02 +0800</pubDate></item><item><title>【2021 ASCO-GI】李志平教授＆成科医生：奥曲肽LAR联合阿昔替尼未明显延长晚期G1/2非胰腺神经内分泌肿瘤患者PFS</title><link>https://mp.weixin.qq.com/s/eZy53IkWCr3UP5HBiD-roA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/0Q6qiaRIrCLiamNZlLFF6C0iaicNurmYm3aNxJEsgqKCqTqPYPOy6RmYXbYSfCBuckSpQtQQ8GKSPx4MGEpEhWAkGg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>2021 ASCO-GI上的一项大会口头报告公布了AXINET研究的最新结果]]></content:encoded><pubDate>Tue, 16 Feb 2021 19:30:02 +0800</pubDate></item><item><title>杨云鹏教授：达伯舒®获批一线非鳞非小细胞肺癌适应证，创新性biomaker探索助力免疫治疗疗效预测</title><link>https://mp.weixin.qq.com/s/EOvZ6st51cOfGP_P_8HKGQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/0Q6qiaRIrCLiamNZlLFF6C0iaicNurmYm3aN0VZpoadQU5puHfRPNR4rhbSbHBQJRVAKsyLbFXEByd4IOoDg5LyGQQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>【肿瘤资讯】近期特别采访了杨云鹏教授，畅谈信迪利单抗新适应证获批的意义，介绍生物标志物探索成果。]]></content:encoded><pubDate>Tue, 16 Feb 2021 19:30:02 +0800</pubDate></item><item><title>【2738】丁克峰教授：拥抱新技术，继续发挥肿瘤外科的主导作用</title><link>https://mp.weixin.qq.com/s/qpR_GSTvXI3l8I2YnGg1ZA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/0Q6qiaRIrCLg2NhmicVkJGvNp1HRClicJicgjbD7fSXibXEEgyHB7Sn06uhuUgtiajkz3tqaUUx2bsu3cWNVPyJP3JhA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>「肿瘤外科资讯」特邀浙江大学医学院附属第二医院的丁克峰教授进行专访，分享肿瘤外科在MDT和患者全程管理中的作用，以及技术创新为肿瘤外科带来的机遇等方面看法。]]></content:encoded><pubDate>Mon, 15 Feb 2021 19:19:49 +0800</pubDate></item><item><title>ASCO GU 2021 |非转移性去势抵抗性前列腺癌中与阿帕他胺长期反应相关的分子决定因素</title><link>https://mp.weixin.qq.com/s/IMUyWALoXeNulvVKoB0ZDQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/0Q6qiaRIrCLg2NhmicVkJGvNp1HRClicJicgZp8tGBiczFMXvlOcvaBHV2XW6RpZ6z3AhtkWDmVRLHOOstCgtyTxC9A/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>一项来自SPARTAN研究的探索性分析，评估了非转移性去势抵抗性前列腺癌(nmCRPC)中与阿帕他胺长期反应相关的分子决定因素。]]></content:encoded><pubDate>Mon, 15 Feb 2021 19:19:49 +0800</pubDate></item><item><title>【2021 ASCO-GI】林榕波教授点评DELIVER研究：肠道菌群基因通路有望预测纳武利尤单抗治疗晚期胃癌的疗效</title><link>https://mp.weixin.qq.com/s/7Iw1C7mNTWTHmv2xtE2SAg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/0Q6qiaRIrCLg2NhmicVkJGvNp1HRClicJicghiag5cXSTmN2lofuLMCV5dMHtDicBf1Umm4rN4GRPc5oeBRgqXV2Uq5w/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>本次与大家分享的是胃食管癌领域的一项口头报告——DELIVER研究，结果提示肠道菌群基因通路有望预测纳武利尤单抗治疗晚期胃癌的疗效。]]></content:encoded><pubDate>Mon, 15 Feb 2021 19:19:49 +0800</pubDate></item></channel></rss>